Clinres Farmacija is operating in the following countries:
Slovenia, Croatia, Serbia, Bosnia & Herzegovina and Macedonia.

In the past, Good Clinical Practice (GCP) compliant, multicenter clinical trials were not common practice in the region we are covering.

Today, region is doubling the number of Clinical trials per year.

Due to turbulent times in the recent past, some countries were almost forgotten and neglected for almost 10 years, but nowadays the whole region is becoming attractive market for the implementation of clinical trials.

The local legislation of Slovenia and Croatia has been fully harmonized with EU standards. Serbian, Macedonian and legislation of Bosnia and Herzegovina still has its own specific requirements but familiarization with these requirements is our expertise.  

Health institutions are adequately equipped with the latest scientific and medical instruments and have highly qualified, experienced staff. Furthermore, the vast majority of investigators from these institutions have extensive experience in leading clinical research strategies both at home and abroad, or at the very least, have conducted trials as part of a global research program and are naturally fluent in English. Incidentally, all countries in the region compared to other countries have the highest percentage of English language speakers in southeastern and central Europe.

Moreover, the region has gained an auspicious reputation for high rates of evaluable subject recruitment, with high patient compliance stemming in part from the confidence that the general public has in the medical profession. This is especially evident in oncology, rare disease, and pediatric clinical trials, which have become increasingly difficult to conduct in Western countries due to considerable patient reluctance. This is not to say that high recruitment rates in region are attributed to some degree of indifference or naivety of the subject, but rather on their immense eagerness to learn and try novel treatments for their ailments. 

The whole region, more than any other southeastern and central Europe country, has radically reinvented and positioned itself as a leading center in Europe for high-quality, cost-efficient clinical studies.

The region we are covering combined with our knowledge gives you the opportunity to get the World class quality results.  

Compared to Western and some other EU countries we can offer lower cost for investigators fees and CRO services without compromising quality.

New studies per year in the region:

Slovenia ~60
Croatia ~100-110
Bosnia and Herzegovina ~40
Serbia ~140
Montenegro ~40-45
Macedonia ~20

• Why choose SEE
• Why choose SEA

 

 

 

 

News archive